UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 1 - 15 of 671

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Pharmacotherapy of the overactive bladder - Abstract
Thursday, 19 November 2009
Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, United States.
read more

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study - Abstract
Wednesday, 18 November 2009
Dipartimento Nefro-Urologico, UOC di Urologia, Naples, Italy.
read more

Urgent® PC and Macroplastique® Abstracts Accepted for Presentation at Society for Urodynamics and Female Urology 2010 Annual Meeting
Tuesday, 17 November 2009
MINNEAPOLIS, MN, USA (Press Release) - November 17, 2009
read more

Extended-release trospium chloride improves quality of life in overactive bladder - Abstract
Tuesday, 17 November 2009
Vanderbilt University School of Medicine, Nashville, TN, USA.
read more

Correlation of thermocouple data with voiding function after prostate cryoablation - Abstract
Monday, 16 November 2009
Department of Regional Urology, Cleveland Clinic Fairview Cancer Center, Glickman Urological and Kidney Institute, Cleveland, OH.
read more

Transabdominal ultrasonography of detrusor wall thickness in women with overactive bladder - Abstract
Monday, 16 November 2009
Division of Urology, Department of Surgery, Far Eastern Memorial Hospital, Ban Ciao, Taipei, Taiwan.
read more

Predictors of response to intradetrusor botulinum toxin-a injections in patients with idiopathic overactive bladder - Abstract
Friday, 13 November 2009
Department of Urology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
read more

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study - Abstract
Thursday, 12 November 2009
Department of Urology, William Beaumont Hospital, Royal Oak, MI, 48073, USA.
read more

Efficacy of darifenacin in patients with varying baseline symptom severity - Abstract
Thursday, 05 November 2009
Vanderbilt University School of Medicine, Department of Urology, A1302, Medical Center North, Nashville, TN 37232, USA.
read more

BJUI Mini Reviews - The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
Tuesday, 03 November 2009
This review provides guidelines for specialized second-line management of OAB after failure with one or more antimuscarinic agents.
Login to read more...

Chronic pudendal neuromodulation: Expanding available treatment options for refractory urologic symptoms - Abstract
Friday, 30 October 2009
Department of Urology, William Beaumont Hospital, Royal Oak, MI.
read more

Validation of the differential cardiovascular effects of the antimuscarinic agents Darifenacin and Tolterodine in a randomized, placebo-controlled, 3-way crossover study - Abstract
Thursday, 29 October 2009
University of Iowa Hospitals, 4426a JCP, 200 Hawkins Drive, Iowa City, Iowa 52242, USA.
read more

Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity - Abstract
Wednesday, 28 October 2009
Division of Urology, University of Utah and Department of Pediatric Urology, Primary Children's Medical Center, Salt Lake City, Utah 84113, USA.
read more

Differential diagnosis of overactive bladder in men - Abstract
Friday, 23 October 2009
State University of New York Downstate Medical School, Brooklyn and Weill Medical College of Cornell University and Lenox Hill Hospital, New York, New York.
read more

IPF 2009 - What has changed in our understanding of BPH? - Session Highlights
Thursday, 22 October 2009
IZMIR, TURKEY (UroToday.com) - Progression of BPH is defined as worsening of AUA-SS of >4 points or urinary retention.
Login to read more...

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder